Lipocine Inc. 8-K

What Happened Lipocine Inc. (LPCN) filed a Form 8-K on May 19, 2026, to announce that its LPCN 1154 Phase 3 data has been accepted for an oral presentation at the 2026 American Society for Clinical Pathology (ASCP) Annual Meeting. The ASCP meeting runs May 26–29, 2026, in Miami, Florida. The company furnished a press release announcing the acceptance as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: May 19, 2026 (Form 8-K, Item 8.01 – Other Events).
• Event: LPCN 1154 Phase 3 data accepted for oral presentation at the 2026 ASCP Annual Meeting.
• Meeting details: ASCP Annual Meeting, May 26–29, 2026, Miami, Florida.
• Press release announcing the acceptance is furnished as Exhibit 99.1 to the 8-K.

Why It Matters An oral presentation at a major scientific meeting is a formal forum for sharing clinical trial results with clinicians, researchers and stakeholders. For investors, this filing confirms that Lipocine will publicly present its Phase 3 data for LPCN 1154 at the ASCP meeting on the specified dates, which may affect the timing and visibility of the company’s clinical data dissemination. The 8-K provides the company’s official disclosure of that upcoming presentation.